Program
Nalbuphine
Also written as “NAL ER”, “nalbuphine HCl ER” and “Nalbuphine Hydrochloride Injection”.
Its studies are mostly in Idiopathic Pulmonary Fibrosis · Prurigo · Pruritus · Chronic Cough · Opioid-Related Disorders, led by 4 companies.
Drug pageNalbuphine: every studyAll 86 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Trevi Therapeuticsits history only | 184 open or running | phase 3since May 17, 2014 | May 17, 2014 | Nov 30, 2026phase 1 · NCT07946575 |
| Lumosa Therapeuticsits history only | 10 open or running | phase 1since May 13, 2015 | May 13, 2015 | none ahead |
| Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceuticalits history only | 10 open or running | phase 3since Apr 1, 2025 | Apr 1, 2025 | none ahead |
| Yung Shin Pharm. Ind. | 10 open or running | phase 4since Jan 27, 2019 | Jan 27, 2019 | none ahead |
Also a collaborator on its studies: Parexel and Davita Clinical Research.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Yung Shin Pharm. Ind. only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Dec 9, 2015Named nalbuphineINNProposed as its International Nonproprietary Name in WHO's List 114
- Jan 27, 2019First study: phase 4 study in Pain, PostoperativeFirst studyNCT03826316 · 14 enrolled · Taiwan
TargetBeta
“Opioid receptors; mu/kappa/delta agonist”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Naltrexonerule | orexigen-therapeutics-inc | phase 4 | 42 |
| nalmefenerule | H. Lundbeck | phase 4 | 20 |
| cebranopadolrule | Tris Pharma | phase 3 | 18 |
Studies
The one study Yung Shin Pharm. Ind. leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03826316Pain, Postoperative · Taiwan | 4 | Completed | Nov 22, 2018 | 14 |
How it is read
Names in the registry
- “NAL ER”, 12 entries
- “nalbuphine HCl ER”, 2 entries
- “Nalbuphine Hydrochloride Injection”, 1 entry
- “Nalbuphine ER”, 1 entry
- “Nalbuphine ER Tablets”, 1 entry
Conditions, from the studies’ own filings
- Idiopathic Pulmonary Fibrosis, 5 studies
- Prurigo, 3 studies
- Pruritus, 3 studies
- Chronic Cough, 2 studies
- Opioid-Related Disorders, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.